Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS) Stock Competitors & Peer Comparison
See (APLS) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| APLS | $40.23 | +135.40% | 5.1B | 223.50 | $0.18 | N/A |
| VRTX | $446.54 | +0.76% | 113.4B | 29.12 | $15.33 | N/A |
| REGN | $772.64 | +3.12% | 80.3B | 18.64 | $41.46 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $730.25 | +3.68% | 45.2B | 37.28 | $19.59 | N/A |
| ALNY | $330.89 | +4.68% | 43.9B | 142.63 | $2.32 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $163.52 | +6.65% | 35.2B | -25.43 | -$6.43 | N/A |
| UTHR | $592.98 | +0.79% | 26B | 21.27 | $27.87 | N/A |
| BNTX | $88.88 | +4.26% | 22.3B | -16.40 | -$5.42 | N/A |
Stock Comparison
APLS vs VRTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, VRTX has a market cap of 113.4B. Regarding current trading prices, APLS is priced at $40.23, while VRTX trades at $446.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas VRTX's P/E ratio is 29.12. In terms of profitability, APLS's ROE is +0.08%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, APLS is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check VRTX's competition here
APLS vs REGN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, REGN has a market cap of 80.3B. Regarding current trading prices, APLS is priced at $40.23, while REGN trades at $772.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas REGN's P/E ratio is 18.64. In terms of profitability, APLS's ROE is +0.08%, compared to REGN's ROE of +0.15%. Regarding short-term risk, APLS is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check REGN's competition here
APLS vs VRNA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, APLS is priced at $40.23, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas VRNA's P/E ratio is -102.80. In terms of profitability, APLS's ROE is +0.08%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, APLS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check VRNA's competition here
APLS vs ARGX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ARGX has a market cap of 45.2B. Regarding current trading prices, APLS is priced at $40.23, while ARGX trades at $730.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ARGX's P/E ratio is 37.28. In terms of profitability, APLS's ROE is +0.08%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, APLS is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ARGX's competition here
APLS vs ALNY Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ALNY has a market cap of 43.9B. Regarding current trading prices, APLS is priced at $40.23, while ALNY trades at $330.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ALNY's P/E ratio is 142.63. In terms of profitability, APLS's ROE is +0.08%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, APLS is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ALNY's competition here
APLS vs SGEN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, APLS is priced at $40.23, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas SGEN's P/E ratio is -57.19. In terms of profitability, APLS's ROE is +0.08%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, APLS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check SGEN's competition here
APLS vs INSM Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, INSM has a market cap of 35.2B. Regarding current trading prices, APLS is priced at $40.23, while INSM trades at $163.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas INSM's P/E ratio is -25.43. In terms of profitability, APLS's ROE is +0.08%, compared to INSM's ROE of -1.68%. Regarding short-term risk, APLS is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check INSM's competition here
APLS vs UTHR Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, UTHR has a market cap of 26B. Regarding current trading prices, APLS is priced at $40.23, while UTHR trades at $592.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas UTHR's P/E ratio is 21.27. In terms of profitability, APLS's ROE is +0.08%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, APLS is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check UTHR's competition here
APLS vs BNTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, BNTX has a market cap of 22.3B. Regarding current trading prices, APLS is priced at $40.23, while BNTX trades at $88.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas BNTX's P/E ratio is -16.40. In terms of profitability, APLS's ROE is +0.08%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, APLS is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check BNTX's competition here
APLS vs RPRX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, RPRX has a market cap of 20.6B. Regarding current trading prices, APLS is priced at $40.23, while RPRX trades at $47.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas RPRX's P/E ratio is 26.95. In terms of profitability, APLS's ROE is +0.08%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, APLS is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check RPRX's competition here
APLS vs BGNE Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, APLS is priced at $40.23, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas BGNE's P/E ratio is -22.55. In terms of profitability, APLS's ROE is +0.08%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, APLS is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check BGNE's competition here
APLS vs MRNA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, MRNA has a market cap of 20.1B. Regarding current trading prices, APLS is priced at $40.23, while MRNA trades at $50.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas MRNA's P/E ratio is -7.00. In terms of profitability, APLS's ROE is +0.08%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, APLS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check MRNA's competition here
APLS vs ROIV Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ROIV has a market cap of 19.8B. Regarding current trading prices, APLS is priced at $40.23, while ROIV trades at $27.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ROIV's P/E ratio is -23.68. In terms of profitability, APLS's ROE is +0.08%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, APLS is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ROIV's competition here
APLS vs RVMD Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, RVMD has a market cap of 19.3B. Regarding current trading prices, APLS is priced at $40.23, while RVMD trades at $97.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas RVMD's P/E ratio is -16.34. In terms of profitability, APLS's ROE is +0.08%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, APLS is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check RVMD's competition here
APLS vs DNA-WT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, APLS is priced at $40.23, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, APLS's ROE is +0.08%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, APLS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check DNA-WT's competition here
APLS vs INCY Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, INCY has a market cap of 18.7B. Regarding current trading prices, APLS is priced at $40.23, while INCY trades at $94.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas INCY's P/E ratio is 14.68. In terms of profitability, APLS's ROE is +0.08%, compared to INCY's ROE of +0.29%. Regarding short-term risk, APLS is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check INCY's competition here
APLS vs GMAB Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, GMAB has a market cap of 16.5B. Regarding current trading prices, APLS is priced at $40.23, while GMAB trades at $26.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas GMAB's P/E ratio is 17.42. In terms of profitability, APLS's ROE is +0.08%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, APLS is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check GMAB's competition here
APLS vs BBIO Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, BBIO has a market cap of 14.4B. Regarding current trading prices, APLS is priced at $40.23, while BBIO trades at $74.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas BBIO's P/E ratio is -19.65. In terms of profitability, APLS's ROE is +0.08%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, APLS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check BBIO's competition here
APLS vs SMMT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, SMMT has a market cap of 14.1B. Regarding current trading prices, APLS is priced at $40.23, while SMMT trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas SMMT's P/E ratio is -13.17. In terms of profitability, APLS's ROE is +0.08%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, APLS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check SMMT's competition here
APLS vs ASND Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, APLS is priced at $40.23, while ASND trades at $228.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ASND's P/E ratio is -52.70. In terms of profitability, APLS's ROE is +0.08%, compared to ASND's ROE of +1.28%. Regarding short-term risk, APLS is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ASND's competition here
APLS vs KRTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, APLS is priced at $40.23, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas KRTX's P/E ratio is -28.09. In terms of profitability, APLS's ROE is +0.08%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, APLS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check KRTX's competition here
APLS vs IONS Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, APLS is priced at $40.23, while IONS trades at $75.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas IONS's P/E ratio is -31.55. In terms of profitability, APLS's ROE is +0.08%, compared to IONS's ROE of -0.69%. Regarding short-term risk, APLS is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check IONS's competition here
APLS vs MDGL Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, MDGL has a market cap of 12B. Regarding current trading prices, APLS is priced at $40.23, while MDGL trades at $523.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas MDGL's P/E ratio is -40.67. In terms of profitability, APLS's ROE is +0.08%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, APLS is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check MDGL's competition here
APLS vs JAZZ Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, APLS is priced at $40.23, while JAZZ trades at $189.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas JAZZ's P/E ratio is -32.37. In terms of profitability, APLS's ROE is +0.08%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, APLS is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check JAZZ's competition here
APLS vs EXEL Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, EXEL has a market cap of 11.5B. Regarding current trading prices, APLS is priced at $40.23, while EXEL trades at $42.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas EXEL's P/E ratio is 15.43. In terms of profitability, APLS's ROE is +0.08%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, APLS is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check EXEL's competition here
APLS vs RNAM Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, APLS is priced at $40.23, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas RNAM's P/E ratio is -17.39. In terms of profitability, APLS's ROE is +0.08%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, APLS is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check RNAM's competition here
APLS vs BMRN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, APLS is priced at $40.23, while BMRN trades at $56.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas BMRN's P/E ratio is 31.38. In terms of profitability, APLS's ROE is +0.08%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, APLS is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check BMRN's competition here
APLS vs RXDX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, APLS is priced at $40.23, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas RXDX's P/E ratio is -56.47. In terms of profitability, APLS's ROE is +0.08%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, APLS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check RXDX's competition here
APLS vs ARWR Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ARWR has a market cap of 8.8B. Regarding current trading prices, APLS is priced at $40.23, while ARWR trades at $62.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ARWR's P/E ratio is 39.19. In terms of profitability, APLS's ROE is +0.08%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, APLS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ARWR's competition here
APLS vs IMGN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, APLS is priced at $40.23, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas IMGN's P/E ratio is -111.55. In terms of profitability, APLS's ROE is +0.08%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, APLS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check IMGN's competition here
APLS vs AXSM Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, AXSM has a market cap of 8.6B. Regarding current trading prices, APLS is priced at $40.23, while AXSM trades at $169.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas AXSM's P/E ratio is -46.05. In terms of profitability, APLS's ROE is +0.08%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, APLS is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check AXSM's competition here
APLS vs PCVX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, APLS is priced at $40.23, while PCVX trades at $58.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas PCVX's P/E ratio is -10.32. In terms of profitability, APLS's ROE is +0.08%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, APLS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check PCVX's competition here
APLS vs BPMC Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, APLS is priced at $40.23, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas BPMC's P/E ratio is -51.58. In terms of profitability, APLS's ROE is +0.08%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, APLS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check BPMC's competition here
APLS vs CERE Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, APLS is priced at $40.23, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CERE's P/E ratio is -16.47. In terms of profitability, APLS's ROE is +0.08%, compared to CERE's ROE of -0.72%. Regarding short-term risk, APLS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check CERE's competition here
APLS vs TECH Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, APLS is priced at $40.23, while TECH trades at $52.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas TECH's P/E ratio is 98.60. In terms of profitability, APLS's ROE is +0.08%, compared to TECH's ROE of +0.04%. Regarding short-term risk, APLS is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check TECH's competition here
APLS vs CYTK Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CYTK has a market cap of 8.1B. Regarding current trading prices, APLS is priced at $40.23, while CYTK trades at $65.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CYTK's P/E ratio is -10.08. In terms of profitability, APLS's ROE is +0.08%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, APLS is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CYTK's competition here
APLS vs IBRX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, APLS is priced at $40.23, while IBRX trades at $7.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas IBRX's P/E ratio is -20.18. In terms of profitability, APLS's ROE is +0.08%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, APLS is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check IBRX's competition here
APLS vs HALO Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, APLS is priced at $40.23, while HALO trades at $64.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas HALO's P/E ratio is 25.25. In terms of profitability, APLS's ROE is +0.08%, compared to HALO's ROE of +0.93%. Regarding short-term risk, APLS is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check HALO's competition here
APLS vs KRYS Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, APLS is priced at $40.23, while KRYS trades at $258.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas KRYS's P/E ratio is 37.71. In terms of profitability, APLS's ROE is +0.08%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, APLS is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check KRYS's competition here
APLS vs NUVL Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, APLS is priced at $40.23, while NUVL trades at $102.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas NUVL's P/E ratio is -17.51. In terms of profitability, APLS's ROE is +0.08%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, APLS is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check NUVL's competition here
APLS vs MTSR Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, APLS is priced at $40.23, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas MTSR's P/E ratio is -23.58. In terms of profitability, APLS's ROE is +0.08%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, APLS is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check MTSR's competition here
APLS vs ABVX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ABVX has a market cap of 7.3B. Regarding current trading prices, APLS is priced at $40.23, while ABVX trades at $111.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ABVX's P/E ratio is -19.96. In terms of profitability, APLS's ROE is +0.08%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, APLS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ABVX's competition here
APLS vs MRUS Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, APLS is priced at $40.23, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas MRUS's P/E ratio is -17.05. In terms of profitability, APLS's ROE is +0.08%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, APLS is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check MRUS's competition here
APLS vs PRAX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, APLS is priced at $40.23, while PRAX trades at $322.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas PRAX's P/E ratio is -23.90. In terms of profitability, APLS's ROE is +0.08%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, APLS is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check PRAX's competition here
APLS vs KYMR Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, KYMR has a market cap of 6.8B. Regarding current trading prices, APLS is priced at $40.23, while KYMR trades at $83.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas KYMR's P/E ratio is -22.57. In terms of profitability, APLS's ROE is +0.08%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, APLS is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check KYMR's competition here
APLS vs PTGX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, APLS is priced at $40.23, while PTGX trades at $105.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas PTGX's P/E ratio is -51.41. In terms of profitability, APLS's ROE is +0.08%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, APLS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check PTGX's competition here
APLS vs ACLX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, APLS is priced at $40.23, while ACLX trades at $114.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ACLX's P/E ratio is -28.21. In terms of profitability, APLS's ROE is +0.08%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, APLS is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check ACLX's competition here
APLS vs RETA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, APLS is priced at $40.23, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas RETA's P/E ratio is -66.29. In terms of profitability, APLS's ROE is +0.08%, compared to RETA's ROE of +0.47%. Regarding short-term risk, APLS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check RETA's competition here
APLS vs BLTE Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, APLS is priced at $40.23, while BLTE trades at $159.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas BLTE's P/E ratio is -69.02. In terms of profitability, APLS's ROE is +0.08%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, APLS is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check BLTE's competition here
APLS vs COGT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, COGT has a market cap of 6.2B. Regarding current trading prices, APLS is priced at $40.23, while COGT trades at $38.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas COGT's P/E ratio is -17.82. In terms of profitability, APLS's ROE is +0.08%, compared to COGT's ROE of -1.00%. Regarding short-term risk, APLS is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check COGT's competition here
APLS vs RYTM Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, APLS is priced at $40.23, while RYTM trades at $86.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas RYTM's P/E ratio is -27.96. In terms of profitability, APLS's ROE is +0.08%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, APLS is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check RYTM's competition here
APLS vs ALKS Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ALKS has a market cap of 5.9B. Regarding current trading prices, APLS is priced at $40.23, while ALKS trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ALKS's P/E ratio is 24.75. In terms of profitability, APLS's ROE is +0.08%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, APLS is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ALKS's competition here
APLS vs CGON Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, APLS is priced at $40.23, while CGON trades at $67.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CGON's P/E ratio is -32.54. In terms of profitability, APLS's ROE is +0.08%, compared to CGON's ROE of -0.23%. Regarding short-term risk, APLS is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CGON's competition here
APLS vs SRRK Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, APLS is priced at $40.23, while SRRK trades at $49.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas SRRK's P/E ratio is -14.94. In terms of profitability, APLS's ROE is +0.08%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, APLS is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check SRRK's competition here
APLS vs PTCT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, APLS is priced at $40.23, while PTCT trades at $68.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas PTCT's P/E ratio is 7.94. In terms of profitability, APLS's ROE is +0.08%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, APLS is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check PTCT's competition here
APLS vs CDTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, APLS is priced at $40.23, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CDTX's P/E ratio is -19.77. In terms of profitability, APLS's ROE is +0.08%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, APLS is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check CDTX's competition here
APLS vs ABCM Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, APLS is priced at $40.23, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, APLS's ROE is +0.08%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, APLS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check ABCM's competition here
APLS vs CELC Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, APLS is priced at $40.23, while CELC trades at $114.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CELC's P/E ratio is -30.12. In terms of profitability, APLS's ROE is +0.08%, compared to CELC's ROE of -2.03%. Regarding short-term risk, APLS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CELC's competition here
APLS vs ISEE Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, APLS is priced at $40.23, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ISEE's P/E ratio is -22.44. In terms of profitability, APLS's ROE is +0.08%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, APLS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check ISEE's competition here
APLS vs FBIOX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, APLS is priced at $40.23, while FBIOX trades at $24.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas FBIOX's P/E ratio is N/A. In terms of profitability, APLS's ROE is +0.08%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, APLS is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check FBIOX's competition here
APLS vs CNTA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CNTA has a market cap of 5.3B. Regarding current trading prices, APLS is priced at $40.23, while CNTA trades at $39.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CNTA's P/E ratio is -21.02. In terms of profitability, APLS's ROE is +0.08%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, APLS is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CNTA's competition here
APLS vs TGTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, TGTX has a market cap of 5.3B. Regarding current trading prices, APLS is priced at $40.23, while TGTX trades at $33.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas TGTX's P/E ratio is 11.99. In terms of profitability, APLS's ROE is +0.08%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, APLS is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check TGTX's competition here
APLS vs IMVT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, APLS is priced at $40.23, while IMVT trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas IMVT's P/E ratio is -9.30. In terms of profitability, APLS's ROE is +0.08%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, APLS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check IMVT's competition here
APLS vs CAI Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, APLS is priced at $40.23, while CAI trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CAI's P/E ratio is -5.55. In terms of profitability, APLS's ROE is +0.08%, compared to CAI's ROE of +0.25%. Regarding short-term risk, APLS is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CAI's competition here
APLS vs ERAS Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, APLS is priced at $40.23, while ERAS trades at $16.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ERAS's P/E ratio is -36.77. In terms of profitability, APLS's ROE is +0.08%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, APLS is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ERAS's competition here
APLS vs TERN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, APLS is priced at $40.23, while TERN trades at $52.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas TERN's P/E ratio is -51.69. In terms of profitability, APLS's ROE is +0.08%, compared to TERN's ROE of -0.30%. Regarding short-term risk, APLS is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check TERN's competition here
APLS vs APGE Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, APLS is priced at $40.23, while APGE trades at $84.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas APGE's P/E ratio is -19.95. In terms of profitability, APLS's ROE is +0.08%, compared to APGE's ROE of -0.37%. Regarding short-term risk, APLS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check APGE's competition here
APLS vs MIRM Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, APLS is priced at $40.23, while MIRM trades at $92.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas MIRM's P/E ratio is -196.55. In terms of profitability, APLS's ROE is +0.08%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, APLS is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check MIRM's competition here
APLS vs XENE Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, APLS is priced at $40.23, while XENE trades at $58.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas XENE's P/E ratio is -13.34. In terms of profitability, APLS's ROE is +0.08%, compared to XENE's ROE of -0.56%. Regarding short-term risk, APLS is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check XENE's competition here
APLS vs CRSP Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, APLS is priced at $40.23, while CRSP trades at $47.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CRSP's P/E ratio is -7.35. In terms of profitability, APLS's ROE is +0.08%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, APLS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CRSP's competition here
APLS vs FOLD Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, APLS is priced at $40.23, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas FOLD's P/E ratio is -160.67. In terms of profitability, APLS's ROE is +0.08%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, APLS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check FOLD's competition here
APLS vs AKRO Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, APLS is priced at $40.23, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas AKRO's P/E ratio is -14.57. In terms of profitability, APLS's ROE is +0.08%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, APLS is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check AKRO's competition here
APLS vs ALPN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, APLS is priced at $40.23, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ALPN's P/E ratio is -101.52. In terms of profitability, APLS's ROE is +0.08%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, APLS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check ALPN's competition here
APLS vs CORT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CORT has a market cap of 4.3B. Regarding current trading prices, APLS is priced at $40.23, while CORT trades at $40.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CORT's P/E ratio is 49.16. In terms of profitability, APLS's ROE is +0.08%, compared to CORT's ROE of +0.15%. Regarding short-term risk, APLS is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CORT's competition here
APLS vs OPT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, APLS is priced at $40.23, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas OPT's P/E ratio is -1.52. In terms of profitability, APLS's ROE is +0.08%, compared to OPT's ROE of +0.88%. Regarding short-term risk, APLS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check OPT's competition here
APLS vs MRTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, APLS is priced at $40.23, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas MRTX's P/E ratio is -4.82. In terms of profitability, APLS's ROE is +0.08%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, APLS is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check MRTX's competition here
APLS vs LGND Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, LGND has a market cap of 4B. Regarding current trading prices, APLS is priced at $40.23, while LGND trades at $199.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas LGND's P/E ratio is 32.62. In terms of profitability, APLS's ROE is +0.08%, compared to LGND's ROE of +0.14%. Regarding short-term risk, APLS is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check LGND's competition here
APLS vs CRNX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CRNX has a market cap of 3.8B. Regarding current trading prices, APLS is priced at $40.23, while CRNX trades at $36.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CRNX's P/E ratio is -7.34. In terms of profitability, APLS's ROE is +0.08%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, APLS is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CRNX's competition here
APLS vs ACAD Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, APLS is priced at $40.23, while ACAD trades at $22.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ACAD's P/E ratio is 9.68. In terms of profitability, APLS's ROE is +0.08%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, APLS is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ACAD's competition here
APLS vs VKTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, APLS is priced at $40.23, while VKTX trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas VKTX's P/E ratio is -10.20. In terms of profitability, APLS's ROE is +0.08%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, APLS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check VKTX's competition here
APLS vs RYZB Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, APLS is priced at $40.23, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas RYZB's P/E ratio is -57.86. In terms of profitability, APLS's ROE is +0.08%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, APLS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check RYZB's competition here
APLS vs CBAY Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, APLS is priced at $40.23, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CBAY's P/E ratio is -32.81. In terms of profitability, APLS's ROE is +0.08%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, APLS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check CBAY's competition here
APLS vs NAMS Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, APLS is priced at $40.23, while NAMS trades at $32.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas NAMS's P/E ratio is -18.61. In terms of profitability, APLS's ROE is +0.08%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, APLS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check NAMS's competition here
APLS vs KNSA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, APLS is priced at $40.23, while KNSA trades at $48.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas KNSA's P/E ratio is 64.20. In terms of profitability, APLS's ROE is +0.08%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, APLS is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check KNSA's competition here
APLS vs SWTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, APLS is priced at $40.23, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas SWTX's P/E ratio is -13.78. In terms of profitability, APLS's ROE is +0.08%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, APLS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check SWTX's competition here
APLS vs EWTX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, EWTX has a market cap of 3.4B. Regarding current trading prices, APLS is priced at $40.23, while EWTX trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas EWTX's P/E ratio is -19.33. In terms of profitability, APLS's ROE is +0.08%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, APLS is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check EWTX's competition here
APLS vs LEGN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, APLS is priced at $40.23, while LEGN trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas LEGN's P/E ratio is -11.17. In terms of profitability, APLS's ROE is +0.08%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, APLS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check LEGN's competition here
APLS vs LQDA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, APLS is priced at $40.23, while LQDA trades at $37.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas LQDA's P/E ratio is -47.17. In terms of profitability, APLS's ROE is +0.08%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, APLS is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check LQDA's competition here
APLS vs TLX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, APLS is priced at $40.23, while TLX trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas TLX's P/E ratio is -478.50. In terms of profitability, APLS's ROE is +0.08%, compared to TLX's ROE of -0.02%. Regarding short-term risk, APLS is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check TLX's competition here
APLS vs DNTH Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, DNTH has a market cap of 3.2B. Regarding current trading prices, APLS is priced at $40.23, while DNTH trades at $83.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas DNTH's P/E ratio is -19.98. In terms of profitability, APLS's ROE is +0.08%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, APLS is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check DNTH's competition here
APLS vs SYRE Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, SYRE has a market cap of 3B. Regarding current trading prices, APLS is priced at $40.23, while SYRE trades at $50.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas SYRE's P/E ratio is -25.47. In terms of profitability, APLS's ROE is +0.08%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, APLS is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check SYRE's competition here
APLS vs DNLI Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, DNLI has a market cap of 3B. Regarding current trading prices, APLS is priced at $40.23, while DNLI trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas DNLI's P/E ratio is -6.46. In terms of profitability, APLS's ROE is +0.08%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, APLS is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check DNLI's competition here
APLS vs CPRX Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, APLS is priced at $40.23, while CPRX trades at $24.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas CPRX's P/E ratio is 14.74. In terms of profitability, APLS's ROE is +0.08%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, APLS is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check CPRX's competition here
APLS vs DYN Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, APLS is priced at $40.23, while DYN trades at $18.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas DYN's P/E ratio is -5.22. In terms of profitability, APLS's ROE is +0.08%, compared to DYN's ROE of -0.61%. Regarding short-term risk, APLS is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check DYN's competition here
APLS vs TARS Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, TARS has a market cap of 3B. Regarding current trading prices, APLS is priced at $40.23, while TARS trades at $70.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas TARS's P/E ratio is -44.12. In terms of profitability, APLS's ROE is +0.08%, compared to TARS's ROE of -0.20%. Regarding short-term risk, APLS is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check TARS's competition here
APLS vs IDYA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, APLS is priced at $40.23, while IDYA trades at $33.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas IDYA's P/E ratio is -26.03. In terms of profitability, APLS's ROE is +0.08%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, APLS is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check IDYA's competition here
APLS vs ARQT Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, ARQT has a market cap of 2.9B. Regarding current trading prices, APLS is priced at $40.23, while ARQT trades at $23.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas ARQT's P/E ratio is -181.23. In terms of profitability, APLS's ROE is +0.08%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, APLS is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check ARQT's competition here
APLS vs VERA Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, APLS is priced at $40.23, while VERA trades at $40.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas VERA's P/E ratio is -8.63. In terms of profitability, APLS's ROE is +0.08%, compared to VERA's ROE of -0.60%. Regarding short-term risk, APLS is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for APLS.Check VERA's competition here
APLS vs MORF Comparison March 2026
APLS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, APLS stands at 5.1B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, APLS is priced at $40.23, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
APLS currently has a P/E ratio of 223.50, whereas MORF's P/E ratio is -14.88. In terms of profitability, APLS's ROE is +0.08%, compared to MORF's ROE of -0.29%. Regarding short-term risk, APLS is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for APLS.Check MORF's competition here